Advertisement
Canada markets open in 30 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7326
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    84.23
    +0.66 (+0.79%)
     

  • Bitcoin CAD

    87,526.55
    +865.71 (+1.00%)
     

  • CMC Crypto 200

    1,389.79
    -6.74 (-0.48%)
     

  • GOLD FUTURES

    2,354.20
    +11.70 (+0.50%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ futures

    17,724.00
    +156.50 (+0.89%)
     

  • VOLATILITY

    15.40
    +0.03 (+0.20%)
     

  • FTSE

    8,124.48
    +45.62 (+0.56%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6833
    +0.0012 (+0.18%)
     
MARKETS LIVE BLOG:

STOCK FUTURES JUMP, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

OliX Pharmaceuticals
·1 min read

SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021.

Sun Woo Hong, Ph.D., head of R&D at OliX Pharmaceuticals, and June Hyun Park, Ph.D., principal scientist at OliX Pharmaceuticals, will be available to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs for OLX703A for hepatitis B virus (HBV), OLX104C for androgenic alopecia (hair loss) and OLX702A for non-alcoholic steatohepatitis (NASH).

To schedule a virtual meeting, please visit the BIO-Europe partneringONE® platform here: https://informaconnect.com/bioeurope/partnering/

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng/

Media Contact:

Jon Yu
ICR Westwicke PR
Phone: +1.475.395.5375
jon.yu@westwicke.com